Senescence-associated secretory factors induced by cisplatin in melanoma cells promote non-senescent melanoma cell growth through activation of the ERK1/2-RSK1 pathway

Although targeted therapy and immunotherapy greatly improve the outcome of melanoma, drug resistance and low response rates still maintain the unsubstitutability of traditional chemotherapy. Cisplatin (CDDP) is widely used in different types of tumours with high response rates, but it generally has...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Xuerong, Shi, Benyan, Zheng, Huiling, Min, Ling, Yang, Jie, Li, Xiaoyi, Liao, Xiaoxin, Huang, Weixing, Zhang, Mingmeng, Xu, Shun, Zhu, Zhe, Cui, Hongjing, Liu, Xinguang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5833767/
https://www.ncbi.nlm.nih.gov/pubmed/29449532
http://dx.doi.org/10.1038/s41419-018-0303-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5833767/
https://www.ncbi.nlm.nih.gov/pubmed/29449532
http://dx.doi.org/10.1038/s41419-018-0303-9

Ejemplares similares